131 related articles for article (PubMed ID: 38523903)
21. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
22. The Impact of Delayed Radical Prostatectomy on Recurrence Outcomes After Initial Active Surveillance: Results from a Large Institutional Cohort.
Shee K; Cowan JE; Washington SL; Shinohara K; Nguyen HG; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38057193
[TBL] [Abstract][Full Text] [Related]
23. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
[TBL] [Abstract][Full Text] [Related]
24. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Amling CL; Dorey F; Kane CJ; Presti JC; Terris MK; Aronson WJ;
Urology; 2002 Oct; 60(4):670-4. PubMed ID: 12385931
[TBL] [Abstract][Full Text] [Related]
25. Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy.
Zattoni F; Nehra A; Murphy CR; Rangel L; Mynderse L; Lowe V; Kwon E; Karnes RJ
Eur Urol Focus; 2016 Dec; 2(5):522-531. PubMed ID: 28723518
[TBL] [Abstract][Full Text] [Related]
26. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.
Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol; 2020 Nov; 78(5):661-669. PubMed ID: 32624288
[TBL] [Abstract][Full Text] [Related]
27. Biochemical disease-free survival in patients with a high prostate-specific antigen level (20-100 ng/mL) and clinically localized prostate cancer after radical prostatectomy.
Brandli DW; Koch MO; Foster RS; Bihrle R; Gardner TA
BJU Int; 2003 Jul; 92(1):19-22; discussion 22-3. PubMed ID: 12823376
[TBL] [Abstract][Full Text] [Related]
28. The presence of prostate-specific antigen checked more than 1 year before diagnostic biopsy is an independent prognostic factor in patients undergoing radical prostatectomy.
Park SG; Shim KH; Choo SH; Kim SJ; Kim SI
Investig Clin Urol; 2021 Jul; 62(4):438-446. PubMed ID: 34085793
[TBL] [Abstract][Full Text] [Related]
29. Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters.
Mazzone E; Gandaglia G; Robesti D; Rajwa P; Gomez Rivas J; Ibáñez L; Soeterik TFW; Bianchi L; Afferi L; Kesch C; Darr C; Guo H; Zhuang J; Zattoni F; Fendler WP; Amparore D; Huebner NA; Giesen A; Joniau S; Schiavina R; Brunocilla E; Mattei A; Dal Moro F; Moreno Sierra J; Porpiglia F; Picchio M; Chiti A; van den Bergh R; Shariat SF; Montorsi F; Briganti A
Eur Urol Oncol; 2024 Apr; 7(2):231-240. PubMed ID: 37689506
[TBL] [Abstract][Full Text] [Related]
30. Significance of Time Until PSA Recurrence After Radical Prostatectomy Without Neo- or Adjuvant Treatment to Clinical Progression and Cancer-Related Death in High-Risk Prostate Cancer Patients.
Venclovas Z; Jievaltas M; Milonas D
Front Oncol; 2019; 9():1286. PubMed ID: 31824859
[No Abstract] [Full Text] [Related]
31. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.
Van den Broeck T; van den Bergh RCN; Arfi N; Gross T; Moris L; Briers E; Cumberbatch M; De Santis M; Tilki D; Fanti S; Fossati N; Gillessen S; Grummet JP; Henry AM; Lardas M; Liew M; Rouvière O; Pecanka J; Mason MD; Schoots IG; van Der Kwast TH; van Der Poel HG; Wiegel T; Willemse PM; Yuan Y; Lam TB; Cornford P; Mottet N
Eur Urol; 2019 Jun; 75(6):967-987. PubMed ID: 30342843
[TBL] [Abstract][Full Text] [Related]
32. Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM) , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study.
Lepor H; Cheli CD; Thiel RP; Taneja SS; Laze J; Chan DW; Sokoll LJ; Mangold L; Partin AW
BJU Int; 2012 Jun; 109(12):1770-5. PubMed ID: 21992499
[TBL] [Abstract][Full Text] [Related]
33. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8.
Manoharan M; Bird VG; Kim SS; Civantos F; Soloway MS
BJU Int; 2003 Oct; 92(6):539-44. PubMed ID: 14511029
[TBL] [Abstract][Full Text] [Related]
34. Tumour characteristics, oncological and functional outcomes in patients aged ≥ 70 years undergoing radical prostatectomy.
Kunz I; Musch M; Roggenbuck U; Klevecka V; Kroepfl D
BJU Int; 2013 Mar; 111(3 Pt B):E24-9. PubMed ID: 22947135
[TBL] [Abstract][Full Text] [Related]
35. Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen.
Eyrich NW; Wei JT; Niknafs YS; Siddiqui J; Ellimoottil C; Salami SS; Palapattu GS; Mehra R; Kunju LP; Tomlins SA; Chinnaiyan AM; Morgan TM; Tosoian JJ
Urol Oncol; 2022 Jan; 40(1):4.e1-4.e7. PubMed ID: 34753659
[TBL] [Abstract][Full Text] [Related]
36. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
Freedland SJ; Vidal AC; Howard LE; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ;
Cancer; 2017 Nov; 123(21):4199-4206. PubMed ID: 28654204
[TBL] [Abstract][Full Text] [Related]
37. Functional and oncological outcomes of patients aged <50 years treated with radical prostatectomy for localised prostate cancer in a European population.
Becker A; Tennstedt P; Hansen J; Trinh QD; Kluth L; Atassi N; Schlomm T; Salomon G; Haese A; Budaeus L; Michl U; Heinzer H; Huland H; Graefen M; Steuber T
BJU Int; 2014 Jul; 114(1):38-45. PubMed ID: 24053677
[TBL] [Abstract][Full Text] [Related]
38. Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?
Boorjian SA; Bianco FJ; Scardino PT; Eastham JA
BJU Int; 2005 Oct; 96(6):773-6. PubMed ID: 16153197
[TBL] [Abstract][Full Text] [Related]
39. Tumor characteristics, oncological and functional outcomes after radical prostatectomy in very young men ≤ 45 years of age.
Tilki D; Maurer V; Pompe RS; Chun FK; Preisser F; Haese A; Graefen M; Huland H; Mandel P
World J Urol; 2020 Jan; 38(1):95-101. PubMed ID: 30937571
[TBL] [Abstract][Full Text] [Related]
40. Oncological and functional outcomes 1 year after radical prostatectomy for very-low-risk prostate cancer: results from the prospective LAPPRO trial.
Carlsson S; Jäderling F; Wallerstedt A; Nyberg T; Stranne J; Thorsteinsdottir T; Carlsson SV; Bjartell A; Hugosson J; Haglind E; Steineck G
BJU Int; 2016 Aug; 118(2):205-12. PubMed ID: 26867018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
